Cystic Fibrosis Canada / Fibrose kystique Canada
Registration:
14
of
31
(2017-09-01
to
2017-11-03)
Grant, Contribution or Other Financial Benefit, Policies or Program
- In terms of research and development, we lobby for support of cystic fibrosis research initiatives that improve the health and wellness of Canadians living with cystic fibrosis.
- In terms of science and technology, we work toward the development of precision and personalized medicines that target the basic defect of cystic fibrosis. We are exploring how the federal government may support these efforts through partnership and funding.
- Increased federal investment in health-related research. We worked with the Health Charities Coalition of Canada (HCCC) to draft content for a press release urging the federal government to invest more in basic science in Canada.
Legislative Proposal, Bill or Resolution
- Advocated for Bill S-201, An Act to Prohibit and Prevent Genetic Discrimination. This Bill received Royal Assent on May 4, 2017.
Policies or Program
- Common Drug Review, importance of meaningful public/patient input into the drug review process
- Encouraging the development of a rare disease strategy in Canada (similar to the policies for rare diseases in Europe and the United States).
- With respect to Health, we advocate for access to cystic fibrosis (CF) medicines and treatments, the development of a rare disease strategy, and for improved access to disability supports for people with CF. This includes any funding required to support the development and implementation of these policy and legislative proposals. The exact amount of funding has yet to be established and would involve further discussions with government officials.
Policies or Program, Regulation
- Health Canada with respect to the regulation of pancreatic enzymes used in the management of cystic fibrosis. Recommend product should be listed on Schedule F to the Food and Drugs Regulations.